⚠ Evidence warning: Clinical trials or other evidence do not support the claim that molybdenum supplements (75–500 mcg/day), a low-sulfur elimination diet, low-dose N-acetylcysteine with molybdenum, and treating gut sulfate-reducing bacteria improve sulfite sensitivity or “sulfur intolerance”. This page keeps it as a report of what people, websites or other media say.

Molybdenum for Sulfite Metabolism

Sulfite Metabolism — scientific infographic poster

Sulfite oxidase — the molybdenum-dependent enzyme that converts toxic sulfite (SO32−) to inert sulfate (SO42−) — is the body's only enzymatic pathway for clearing sulfite. There is no backup. When sulfite oxidase fails (in molybdenum cofactor deficiency or isolated sulfite oxidase deficiency), sulfite accumulates within hours and destroys developing brain tissue. When it merely runs at low capacity (in some asthmatics, in some individuals with the SUOX low-activity polymorphism), the result is sulfite sensitivity — bronchospasm and anaphylactoid reactions to preserved wine, dried fruits, and processed foods. This page covers the molecular biology of sulfite oxidase, the catastrophic pediatric phenotypes, sulfite sensitivity in adults, the role of cruciferous vegetables and other high-sulfur foods, the interaction with glutathione and the methylation cycle, and practical dietary and supplementation strategies.


Table of Contents

  1. The Biology of Sulfite Oxidase
  2. Sources of Sulfite: Endogenous and Exogenous
  3. How Sulfite Damages Cells
  4. Isolated Sulfite Oxidase Deficiency
  5. Sulfite Sensitivity in Adults
  6. Sulfites and Asthma (The Wine and Salad Bar Story)
  7. Cruciferous Vegetables and the Sulfur Load
  8. Interaction with Glutathione and Methylation
  9. Improving Tolerance for High-Sulfur Diets
  10. Dietary Strategies for Sulfite-Sensitive Patients
  11. Molybdenum Supplementation Considerations
  12. Key Research Papers
  13. Connections
  14. Featured Videos

The Biology of Sulfite Oxidase

Sulfite oxidase (SUOX) is a 110 kDa homodimeric enzyme located in the mitochondrial intermembrane space. Each monomer contains:

The catalytic mechanism: sulfite binds at the molybdenum center, where an oxygen atom is transferred from a molybdenum-bound oxo group to the sulfur of sulfite, producing sulfate. The molybdenum cycles between Mo(VI) and Mo(IV) oxidation states during the reaction. The electrons released are passed first to the heme cytochrome b5 domain within the enzyme, then to cytochrome c in the mitochondrial respiratory chain, which feeds them into complex IV for adenosine triphosphate (ATP) production. The overall reaction is therefore not just detoxification but also a modest energy capture — sulfite oxidation contributes electrons to the respiratory chain.

SUOX is expressed in essentially every cell type, with highest expression in liver, kidney, heart, and brain. Brain expression is particularly important because the blood-brain barrier limits sulfite efflux, and developing neurons appear to be the most vulnerable cell type to sulfite toxicity.

The gene encoding sulfite oxidase, SUOX, sits on chromosome 12q13.2. Over 30 disease-causing mutations have been characterized, distributed across the molybdenum-binding domain, the heme domain, and the dimerization interface. Compound heterozygotes for two severe loss-of-function alleles develop isolated sulfite oxidase deficiency in the neonatal period. Heterozygotes with one functional allele appear clinically normal, though they may have measurably reduced enzyme activity and possibly increased sulfite-sensitive symptoms under high sulfite challenge.

Back to Table of Contents

Sources of Sulfite: Endogenous and Exogenous

Sulfite (SO32−) reaches the body through two distinct routes that the same sulfite oxidase must handle:

Endogenous sulfite is the larger source by mass. The catabolism of the sulfur amino acids methionine and cysteine generates sulfite as a penultimate intermediate. The cysteine sulfinic acid pathway produces sulfite directly. The transsulfuration pathway feeds methionine through homocysteine and cystathionine to cysteine, which then enters the same sulfite-generating catabolic route. A typical adult consuming the Recommended Dietary Allowance (RDA) of protein produces approximately 25–30 millimoles of sulfite per day endogenously — far more than typical dietary sulfite intake.

Exogenous sulfite from sulfiting preservatives is the variable, more dramatic source. The major sulfiting agents in food and pharmaceuticals are:

High-sulfite foods and beverages:

The 1986 U.S. Food and Drug Administration (FDA) labeling rule requires sulfites at or above 10 ppm to be declared on the ingredient label. The pharmaceutical labeling rule from 1987 requires similar disclosure on drug packaging.

Back to Table of Contents

How Sulfite Damages Cells

Sulfite is a small, highly reactive nucleophile that damages cells through several distinct mechanisms:

  1. Disulfide bond disruption — sulfite reacts with the disulfide bonds (S−S) that hold protein tertiary structure together, cleaving them to S-sulfocysteine and free thiol. This destroys protein folding and inactivates enzymes, receptors, and structural proteins. The eye lens is particularly vulnerable because the lens proteins (crystallins) depend on intramolecular disulfides for transparency; this is why lens subluxation is a defining feature of severe sulfite oxidase deficiency.
  2. S-sulfocysteine formation — sulfite reacts with cysteine to form S-sulfocysteine, a structural analog of glutamate. S-sulfocysteine activates N-methyl-D-aspartate (NMDA) receptors and other glutamate receptors, producing excitotoxic neuronal injury. This is the molecular basis for the neonatal seizures of sulfite oxidase deficiency.
  3. Sulfite radical generation — under oxidative conditions, sulfite can undergo one-electron oxidation to sulfite radical anion (SO3−), which propagates lipid peroxidation chain reactions and damages membranes, DNA, and mitochondrial components.
  4. Glutathione depletion — sulfite reacts with glutathione (reduced glutathione, GSH) via the cysteinyl thiol, depleting the cell's most abundant antioxidant. Glutathione depletion sensitizes cells to all forms of oxidative injury.
  5. Mast cell degranulation — sulfite directly triggers mast cell degranulation independent of immunoglobulin E (IgE), releasing histamine, leukotrienes, and prostaglandins. This is the proposed mechanism for the urticaria, angioedema, and anaphylactoid reactions seen in sulfite-sensitive patients.
  6. Parasympathetic airway reflex — inhaled sulfite (from gas evolving in the stomach after ingestion, or from inhaler preservatives) triggers parasympathetic bronchoconstriction via vagal afferent stimulation. This is a major mechanism in sulfite-induced asthma.

Back to Table of Contents

Isolated Sulfite Oxidase Deficiency

Isolated sulfite oxidase deficiency (ISOD) is a rare autosomal recessive disorder caused by biallelic loss-of-function mutations in the SUOX gene. Unlike molybdenum cofactor deficiency (MoCD), where all three molybdoenzymes fail, ISOD selectively eliminates sulfite oxidase — xanthine oxidase and aldehyde oxidase remain functional. Clinical presentation is therefore dominated by pure sulfite toxicity.

Classical (severe) ISOD presents in the first days of life with:

Biochemistry shows elevated urinary sulfite (urine test strips can detect it, although the 2024 consensus guidelines point to a lack of easily available and reliable diagnostic tests for these disorders), elevated S-sulfocysteine, elevated thiosulfate, decreased urinary sulfate, normal uric acid (distinguishing ISOD from MoCD where xanthine oxidase failure produces low uric acid), and normal urinary xanthine.

A 2025 analysis of 74 published ISOD cases found that symptoms began at a median age of 3 days, but diagnosis came at a median age of 10 months. In 2024 an international group of experts published consensus guidelines for diagnosing and managing ISOD and molybdenum cofactor deficiencies. They describe diagnosis as often delayed because the newborn brain illness (acute neonatal encephalopathy) looks non-specific and easily available, reliable tests are lacking, and they report significant variation in survival and in the quality of symptom care.

A milder late-onset / atypical ISOD phenotype has been described in older children and adults with residual sulfite oxidase activity, presenting with movement disorders, developmental delay, and intermittent neurological symptoms. These cases often go undiagnosed for years.

No specific replacement therapy exists for ISOD. Unlike MoCD type A, where exogenous cyclic pyranopterin monophosphate can rescue the cofactor biosynthesis defect, the SUOX protein itself is what's missing in ISOD — and protein replacement therapy for mitochondrial enzymes has not yet been developed. A synthetic cyclic pyranopterin monophosphate (cPMP), fosdenopterin, was approved by the US Food and Drug Administration for reducing the risk of death in children and adults with MoCD type A, a 2021 review reports; the 2024 consensus guidelines name MoCD type A as the one of the four sulfite-intoxication disorders that has become treatable at its cause with synthetic cPMP, and call the evidence base for its use “very limited”. Management of ISOD is supportive: aggressive dietary sulfur restriction (low methionine and cysteine), seizure control, and prevention of further sulfite exposure provide only partial benefit. In a 2000 report of two children with a mild, late-onset form of ISOD, a diet low in natural protein (methionine 130–150 mg a day) plus a synthetic amino acid mixture (50 g a day) without cystine and methionine brought a dramatic fall in urinary thiosulfate and S-sulfocysteine; after 2 years both children were growing normally with no signs of neurological deterioration. The 2005 review of all published cases found clinical improvement with diet in only 2 patients, both of whom presented after 6 months of age and had relatively mild developmental delays. Several research groups are pursuing gene therapy approaches.

Back to Table of Contents

Sulfite Sensitivity in Adults

Sulfite sensitivity affects an estimated 1% of the general population; among people with asthma who ingest sulfite additives, most studies report a prevalence of 3–10%, a 2012 review found. Severity ranges from mild gastrointestinal symptoms after a glass of wine to fatal anaphylactoid reactions requiring emergency epinephrine.

Symptom categories:

The mechanism is not immunoglobulin E-mediated true allergy. Most sulfite-sensitive patients have negative skin prick and serum-specific immunoglobulin E tests for sulfite. Proposed mechanisms include:

The 2012 review notes that although a number of potential mechanisms have been proposed, the precise mechanisms underlying sulfite sensitivity remain unclear.

Risk factors for sulfite sensitivity include preexisting asthma (especially steroid-dependent), atopic dermatitis, chronic rhinitis, possibly the SUOX low-activity polymorphisms, and underlying mast cell activation syndromes. The 2012 review adds that steroid-dependent asthmatics, people with marked airway hyperresponsiveness, and children with chronic asthma appear to be at greater risk.

Diagnosis is typically clinical (correlation of symptoms with high-sulfite exposures) confirmed by oral sulfite challenge under medical supervision when uncertain. Skin prick testing is not useful because the reaction is not immunoglobulin E-mediated.

Back to Table of Contents

Sulfites and Asthma (The Wine and Salad Bar Story)

The link between sulfites and severe asthma was established in dramatic fashion in the early 1980s when the U.S. Food and Drug Administration received reports of multiple deaths from asthma attacks triggered by sulfite-sprayed salad bar produce. Restaurants commonly sprayed cut fruits and vegetables with sulfite solutions to prevent browning; patrons would consume the produce and develop severe bronchospasm within minutes. Investigation linked the deaths to the sulfite spray practice; the U.S. Food and Drug Administration banned use of sulfites on fresh fruits and vegetables intended to be served raw in 1986.

The same year, the U.S. Food and Drug Administration mandated sulfite labeling on packaged foods at the 10 ppm threshold. Subsequent epidemiology refined the picture: most studies report that 3–10% of asthmatics who ingest sulfite additives are sulfite-sensitive, with the highest prevalence in steroid-dependent and severe asthma. The reaction is rapid (typically within 5–30 minutes of exposure), correlates with sulfite dose, and can be reproduced by oral sulfite challenge under controlled conditions.

The wine reaction is the most commonly recognized sulfite trigger today. Wines must contain sulfites to inhibit microbial spoilage and oxidation during fermentation and aging; legal limits in the US are 350 ppm, with most commercial wines in the 50–200 ppm range. Sulfite-sensitive asthmatics often report wheezing within 5–15 minutes of wine consumption. "No sulfite added" wines (containing only the small amount produced naturally by yeast fermentation, typically <10 ppm) are often better tolerated. Red wines generally contain less added sulfite than whites because the natural antioxidants in red wine (tannins, anthocyanins) provide partial preservative effect.

For patients with sulfite-sensitive asthma, the inhaled bronchodilator emergency may itself be problematic — some metered-dose inhaler preparations contain sulfites as preservative. Inhaler ingredient lists name any sulfite preservative, and sulfite-free formulations are available for most major bronchodilators.

Back to Table of Contents

Cruciferous Vegetables and the Sulfur Load

Cruciferous vegetables (broccoli, cauliflower, Brussels sprouts, cabbage, kale, bok choy, arugula, mustard greens, radish, watercress, horseradish) are notable for their high content of glucosinolates — sulfur-containing secondary metabolites that yield isothiocyanates (sulforaphane, indole-3-carbinol, others) upon plant cell rupture. These compounds are widely celebrated for chemopreventive effects via Nrf2 activation and phase II enzyme induction.

However, cruciferous vegetables also contribute meaningful sulfur load to the body. The total sulfur content of a typical broccoli serving is approximately 100–200 mg, much of which enters the methionine-cysteine metabolic pool and eventually generates sulfite that must be cleared by sulfite oxidase. For individuals with limited sulfite oxidase capacity (genetic polymorphisms, suboptimal molybdenum status, or active inflammation), heavy cruciferous intake can produce symptoms of "sulfur intolerance" that overlap with sulfite sensitivity:

The "sulfur intolerance" phenotype is being increasingly recognized in functional and integrative medicine circles, though it has not been formally codified in standard medical references. Practitioners in these circles describe a trial of low-sulfur diet (leaving out cruciferous vegetables, alliums, eggs, and animal protein for 2–4 weeks) with symptom tracking, followed by reintroduction. For people who improve on the low-sulfur diet, they describe molybdenum supplementation (75–500 mcg/day) to support sulfite oxidase capacity before gradually reintroducing high-sulfur foods.

Back to Table of Contents

Interaction with Glutathione and Methylation

Sulfite metabolism is intertwined with two of the body's most important sulfur-dependent biochemical systems: glutathione synthesis and the methylation cycle.

Glutathione (reduced glutathione) is the tripeptide gamma-glutamyl-cysteinyl-glycine, the body's dominant intracellular antioxidant and the cofactor for phase II conjugation reactions. The rate-limiting amino acid for glutathione synthesis is cysteine, which is derived from the catabolism of methionine via the transsulfuration pathway. This same pathway produces sulfite as a downstream metabolite.

The interplay:

The methylation cycle connects through homocysteine. Homocysteine sits at a branch point: it can be remethylated back to methionine (via folate/B12 or via betaine), or it can be committed to transsulfuration toward cysteine (via cystathionine beta-synthase, requiring vitamin B6). The choice depends on methionine availability and cellular demand for cysteine/glutathione. When the transsulfuration arm runs at high flux (high cysteine/glutathione demand), sulfite generation is also high, placing demand on sulfite oxidase.

For people with methylation cycle dysfunction (elevated homocysteine, methylenetetrahydrofolate reductase (MTHFR) polymorphisms, cystathionine beta-synthase (CBS) upregulation polymorphisms), functional medicine practitioners pay attention to molybdenum status to support sulfite oxidase capacity. Some functional medicine protocols specifically include molybdenum (typically 75–500 mcg/day) when managing patients with elevated transsulfuration flux.

The interaction with N-acetylcysteine (NAC) is worth noting: N-acetylcysteine provides direct cysteine for glutathione synthesis, but in patients with severely limited sulfite oxidase capacity, large N-acetylcysteine doses can paradoxically worsen sulfur-intolerance symptoms because the cysteine load eventually generates sulfite. Practitioners describe starting N-acetylcysteine at low doses (300–600 mg/day) together with molybdenum supplementation for sulfite-sensitive people who are seeking glutathione support.

Back to Table of Contents

Improving Tolerance for High-Sulfur Diets

Many of the foods most prized by health-conscious eaters — cruciferous vegetables, alliums (garlic, onion, leek), pasture-raised eggs, grass-fed beef, organ meats, salmon, sardines, and bone broth — are high in sulfur amino acids. Patients who develop intolerance to these foods often face a difficult choice between symptom management and the nutritional benefits of a sulfur-rich diet.

Strategies practitioners describe for improving tolerance of high-sulfur foods:

Back to Table of Contents

Dietary Strategies for Sulfite-Sensitive Patients

For people with confirmed or suspected sulfite sensitivity, dietary management focuses on minimizing exogenous sulfite exposure while addressing the underlying capacity limitation:

Back to Table of Contents

Molybdenum Supplementation Considerations

For adults with sulfite sensitivity, sulfur intolerance, or chronic exposure to dietary or environmental sulfites, practitioners describe molybdenum supplementation as a low-cost, low-risk intervention that may improve sulfite oxidase capacity. The practices they describe:

Back to Table of Contents

Key Research Papers

  1. Schwarz G, Belaidi AA (2013). Molybdenum in human health and disease. Metal Ions in Life Sciences. — PubMed PMID: 24470099
  2. Bender D, Kaczmarek AT, Santamaria-Araujo JA, Stueve B, Waltz S, Bartsch D, Kurian L, Cirak S, Schwarz G (2019). Impaired mitochondrial maturation of sulfite oxidase in a patient with severe sulfite oxidase deficiency. Human Molecular Genetics. — PubMed PMID: 31127934
  3. Tan WH et al. (2005). Isolated sulfite oxidase deficiency: a case report with a novel mutation and review. Pediatrics. — PubMed PMID: 16140720
  4. Vally H, Misso NL (2012). Adverse reactions to the sulphite additives. Gastroenterology and Hepatology from Bed to Bench. — PubMed PMID: 24834193
  5. Simon RA (1998). Update on sulfite sensitivity. Allergy. — PubMed PMID: 9826006
  6. Mendel RR, Bittner F (2006). Cell biology of molybdenum. Biochimica et Biophysica Acta. — PubMed PMID: 16784786
  7. Belaidi AA, Schwarz G (2013). Metal insertion into the molybdenum cofactor. Biochemical Journal. — PubMed PMID: 23163752
  8. Rajagopalan KV, Johnson JL (1992). The pterin molybdenum cofactors. Journal of Biological Chemistry. — PubMed PMID: 1587808
  9. Touati G, Rusthoven E, Depondt E, Dorche C, Duran M, Heron B, Rabier D, Russo M, Saudubray JM (2000). Dietary therapy in two patients with a mild form of sulphite oxidase deficiency. Evidence for clinical and biological improvement. Journal of Inherited Metabolic Disease. — PubMed PMID: 10682307
  10. Veldman A et al. (2010). Successful treatment of molybdenum cofactor deficiency type A with cPMP. Pediatrics. — PubMed PMID: 20385644
  11. Kang C (2021). Fosdenopterin: First Approval. Drugs. — PubMed PMID: 33909276
  12. Schwahn BC, van Spronsen F, Misko A, Pavaine J, Holmes V, Spiegel R, Schwarz G, Wong F, Horman A, Pitt J, Sass JO, Lubout C (2024). Consensus guidelines for the diagnosis and management of isolated sulfite oxidase deficiency and molybdenum cofactor deficiencies. Journal of Inherited Metabolic Disease. — PubMed PMID: 38627985
  13. Göde L, Zielonka M, Garbade SF, Posset R (2025). Ultra-orphan diseases: A cross-sectional quantitative analysis of the natural history of isolated sulfite oxidase deficiency. PLoS One. — PubMed PMID: 40440599

PubMed Topic Searches

  1. PubMed: Sulfite oxidase / SUOX
  2. PubMed: Sulfite sensitivity asthma
  3. PubMed: Isolated sulfite oxidase deficiency
  4. PubMed: Transsulfuration cysteine glutathione
  5. PubMed: Sulfite/sulfate metabolism humans

Back to Table of Contents

Connections

Back to Table of Contents